Higher IOP may be marker for CVD

Article

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea.

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea published in the British Journal of Ophthalmology. The researchers found that higher IOP is associated with the presence of coronary artery calcium (CAC) in asymptomatic patients, regardless of the presence of usual cardiovascular risk factors.

The researchers’ cross-sectional study included 10,732 men and women without diagnoses of CVD or glaucoma. They measured CAC using cardiac computed tomography and IOP using a non-contact tonometer and automatic air puff control.

The researchers detected CAC in 13.7% in men and 4.3% of women. They found that increasing levels of right IOP were significantly associated with an increased prevalence of CAC. They adjusted for multiple factors - age, sex, tobacco use, alcohol use, physical activity, body mass index, educational level, centre, family history of CVD, use of dyslipidemia medication, diabetes, hypertension, total cholesterol level, high-density lipoprotein cholesterol and triglycerides - and found that the odds ratios for CAC score >0, comparing 2–4 quartiles of the right IOP with the lowest quartiles, were 1.32, 1.20 and 1.28, respectively. The associations were the same among the clinically relevant subgroups.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.